PTK2 and neoplasm: One of the first clinically available dual-specific inhibitor was PF-562271, an ATP-competitive reversible inhibitor of the catalytic activity for FAK and Pyk2 that was effective in inducing tumour regression [75] and in reducing tumour growth, invasion, and metastatisation [76] in preclinical studies on mouse xenograft models.